Hub : Traits :

Breast Cancer

1536 significantly associated models · 291 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	9395261	11390336	5	1	7.5e-17	2.5e-20	6.0e-05	81	PEX14
2	1	18560488	19059839	1	1	5.0e-16	1.2e-12	6.7e-01	100	KLHDC7A
3	1	40173354	40680128	1	1	1.2e-07	2.7e-05	5.4e-01	98	MFSD2A
4	1	44623428	46844530	6	1	2.5e-08	3.0e-08	1.5e-02	81	GPBP1L1
5	1	109513274	110936557	3	1	5.1e-08	9.2e-07	9.4e-04	55	GSTM1
6	1	113541801	115152814	3	1	4.4e-09	4.4e-11	2.7e-03	79	DCLRE1B
7	1	117708477	119169364	1	1	5.0e-09	1.7e-10	2.7e-04	68	GDAP2
8	1	120208297	121312687	3	3	2.4e-50	1.8e-52	1.0e+00	100	HIST2H2BA
9	1	144896319	145747463	3	1	4.3e-13	2.3e-10	2.2e-03	77	ANKRD34A
10	1	149672809	150515021	3	1	1.3e-09	1.1e-14	1.3e-06	61	RP11-196G18.24
11	1	154462360	156838141	20	2	3.3e-11	4.8e-11	8.9e-01	100	GBAP1 SEMA4A
12	1	203068720	204522489	2	2	3.7e-08	2.1e-10	NaN	NaN	SNRPE ZC3H11A
13	2	24324172	25889403	4	1	3.3e-12	1.0e-11	2.7e-01	97	ADCY3
14	2	68993402	69723710	1	1	7.0e-10	9.6e-08	7.1e-04	60	ANTXR1
15	2	120301828	121747406	1	1	3.7e-10	5.3e-20	5.1e-18	11	RALB
16	2	171683107	173097928	1	1	3.2e-08	6.2e-12	1.9e-10	14	CYBRD1
17	2	201131124	203176201	6	1	4.4e-17	1.4e-16	1.0e+00	100	ALS2CR12
18	2	217908472	218866036	1	3	7.5e-17	3.2e-93	5.6e-93	0	DIRC3
19	3	26563909	28211713	2	6	1.3e-60	5.2e-63	NaN	NaN	NEK10 SLC4A7
20	3	46463424	47958037	3	3	3.8e-10	5.8e-19	NaN	NaN	KIF9-AS1 PRSS45
21	3	63121945	64684683	4	1	2.1e-12	3.0e-12	1.0e+00	100	ATXN7
22	3	98838914	100872536	7	1	1.8e-10	5.2e-10	1.2e-01	94	C3orf26
23	3	140350567	141867638	1	1	1.0e-13	2.9e-14	1.0e+00	100	ZBTB38
24	3	155768424	157226796	1	1	2.0e-07	6.8e-07	3.6e-01	97	LINC00886
25	4	38097478	39643536	3	1	3.6e-11	1.5e-12	1.2e-02	87	TLR1
26	4	83635581	85097232	3	1	1.9e-09	6.3e-09	1.4e-01	94	MRPS18C
27	4	88937491	89452479	1	1	1.3e-09	1.6e-09	1.5e-01	94	PPM1K
28	5	12225	1546049	2	2	1.2e-07	3.9e-19	1.0e-19	-3	EXOC3 ZDHHC11
29	5	44048891	45516364	3	5	4.8e-58	4.8e-58	1.0e+00	100	MRPS30 RP11-53O19.1 RP11-53O19.3
30	5	49462228	50836718	1	1	1.5e-07	1.5e-08	3.7e-06	33	PARP8
31	5	55509554	56923759	5	10	7.5e-67	8.8e-98	NaN	NaN	C5orf35 CTD-2310F14.1 MAP3K1 MIER3 SETD9
32	5	80580063	82378422	3	1	3.8e-13	8.9e-13	2.0e-01	97	ATG10
33	5	90431779	90941201	1	1	1.0e-08	9.0e-12	1.9e-04	70	LOC100129716
34	5	130830617	133140038	5	2	1.3e-08	9.4e-09	1.0e+00	100	HSPA4 UQCRQ
35	6	12934687	14408104	2	1	2.1e-10	6.4e-13	2.5e-05	66	RANBP9
36	6	42946943	43442756	1	1	2.0e-07	1.7e-06	4.9e-01	98	C6orf108
37	6	80481695	81872212	1	1	5.4e-09	3.1e-09	1.1e-01	93	RP11-250B2.5
38	6	122034905	123452449	1	1	3.9e-08	2.3e-06	5.2e-02	83	HSF2
39	6	129638583	131163098	2	1	6.2e-14	3.0e-12	9.2e-01	100	RP11-73O6.3
40	6	151569243	152184020	1	3	1.0e-29	4.8e-54	5.5e-25	56	C6orf97
41	7	90874777	92571165	6	1	5.2e-11	5.1e-11	2.6e-01	97	CYP51A1
42	7	93516077	94977637	1	1	1.5e-12	5.5e-13	6.6e-02	94	SGCE
43	7	101420819	102943552	3	3	8.6e-08	1.2e-11	9.2e-09	28	POLR2J RASA4
44	7	143425361	144768633	1	1	4.8e-12	1.2e-11	1.0e+00	100	ARHGEF5
45	8	75200357	76725867	2	2	1.7e-10	3.1e-24	3.9e-15	40	CRISPLD1 HNF4G
46	8	123814825	125250560	1	1	1.3e-08	2.2e-12	4.1e-15	-25	FBXO32
47	8	128107136	129812343	1	1	7.5e-21	8.1e-62	3.0e-45	28	PVT1
48	9	21303958	22705094	1	1	2.0e-13	1.2e-19	2.5e-08	62	CDKN2B
49	9	106163708	107600193	1	1	1.1e-08	1.9e-07	1.0e+00	100	SMC2
50	10	21087485	22724472	2	1	1.0e-12	1.8e-19	2.6e-08	62	MLLT10
51	10	64195778	65606229	2	2	6.3e-09	1.6e-49	4.7e-44	12	ADO NRBF2
52	10	113511441	115622375	2	1	8.4e-14	1.0e-14	1.2e-14	1	TCF7L2
53	10	122801759	124407934	2	3	7.1e-12	0.0e+00	3.3e-294	6	ATE1 RP11-500G22.2
54	11	198510	2705175	21	3	9.0e-34	6.3e-33	1.7e-03	93	RNH1 RPLP2 TNNT3
55	11	64721908	67294308	14	2	7.8e-13	3.9e-12	2.6e-02	90	C11orf80 DKFZp761E198
56	11	68227852	70159781	2	2	8.5e-09	2.8e-43	5.6e-37	15	CCND1 RP11-554A11.9
57	11	110908587	112335631	1	1	2.2e-08	2.5e-07	7.4e-01	100	PPP2R1B
58	14	68037895	69442848	1	1	2.8e-07	6.5e-42	4.4e-37	12	RAD51L1
59	14	91042968	93847625	3	3	1.8e-12	8.2e-13	4.8e-07	50	CCDC88C GPR68 RIN3
60	14	104497543	105959867	5	1	7.4e-09	5.9e-08	9.1e-01	100	RP11-982M15.2
61	15	63099535	64579572	1	1	2.2e-07	6.6e-05	1.6e-03	37	USP3
62	15	74431715	76613093	5	2	6.5e-09	2.9e-07	3.5e-01	97	MAN2C1 ULK3
63	15	90776375	92225560	5	7	9.5e-16	1.9e-15	1.0e+00	100	AC068831.6 FES RCCD1
64	16	3304762	4855279	1	1	1.6e-07	2.6e-06	5.0e-02	83	ADCY9
65	16	52222053	52828325	1	1	3.1e-168	6.9e-201	3.6e-39	81	TOX3
66	16	55697964	57248479	3	1	1.2e-09	6.3e-08	6.9e-02	89	BBS2
67	16	80392506	81087529	1	1	3.3e-27	6.2e-27	1.0e+00	100	CDYL2
68	17	28559182	30034689	2	1	4.4e-10	1.4e-09	3.8e-04	66	RP11-848P1.7
69	17	39993748	41393295	3	1	1.2e-08	1.7e-07	1.4e-06	15	NAGLU
70	17	42774693	45796313	16	1	1.2e-11	1.8e-10	1.0e+00	100	LRRC37A4P
71	17	52287259	54097059	5	1	2.1e-27	1.1e-28	1.0e+00	100	STXBP4
72	17	77072043	78469357	1	1	3.5e-10	3.9e-10	1.0e+00	100	CBX8
73	18	24020065	24532336	1	1	1.2e-07	3.2e-17	1.9e-18	-8	LOC728606
74	19	12365196	13960562	4	1	5.9e-11	1.1e-08	1.8e-10	-25	IER2
75	19	16699813	20451172	20	3	2.8e-28	2.8e-28	1.0e+00	100	ANKLE1 GATAD2A SSBP4
76	19	43422999	45202640	8	2	9.6e-18	1.4e-16	3.2e-01	99	KCNN4 PINLYP
77	20	48109475	49505582	1	1	1.1e-11	9.9e-10	3.7e-02	88	CEBPB
78	22	28125740	30357801	5	2	1.6e-16	2.8e-11	2.2e-01	97	CHEK2 RHBDD3
79	22	37643564	41895409	14	10	1.7e-33	1.1e-34	NaN	NaN	ADSL APOBEC3A BAIAP2L2 C22orf23 MCHR1 MKL1 SLC25A17

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Breast cancer (self-reported)	7.44	14	7	15.6	-0.98	1.1e-13	C6orf97 CDYL2 CTD-2310F14.1 CYBRD1 HIST2H2BA MCHR1 MIER3 MKL1 NEK10 PVT1 RP11-53O19.1 RP11-53O19.3 SLC4A7 TOX3
Heel T-Score	5.99	28	22	48.9	0.29	1.1e-01	ADCY9 ADSL ATE1 C22orf23 C6orf97 CEBPB CHEK2 CTD-2310F14.1 CYBRD1 CYP51A1 DIRC3 GBAP1 HSPA4 LINC00886 LRRC37A4P MKL1 NEK10 PEX14 PINLYP RHBDD3 RP11-196G18.24 RP11-500G22.2 RP11-554A11.9 RP11-73O6.3 SLC25A17 SSBP4 USP3 ZBTB38
Heel bone mineral density (BMD) T-score, automated (left)	4.39	4	1	2.2	0.43	3.9e-01	ATE1 C6orf97 MKL1 RP11-73O6.3
Heel bone mineral density (BMD) T-score, automated (right)	3.92	4	2	4.4	0.74	8.9e-02	ATE1 C6orf97 RP11-500G22.2 ZBTB38
Comparative body size at age 10	2.90	8	6	13.3	0.11	7.7e-01	ADCY3 ADCY9 ADSL C6orf108 DKFZp761E198 GATAD2A MKL1 SLC25A17
Systolic Blood Pressure	2.85	20	13	28.9	-0.34	9.7e-02	ADCY3 ADCY9 ADO ADSL CRISPLD1 CYBRD1 CYP51A1 FES GPBP1L1 HSPA4 LRRC37A4P MKL1 NAGLU NEK10 RIN3 SLC4A7 TCF7L2 TNNT3 TOX3 ULK3
Height	2.81	38	30	66.7	-0.02	8.9e-01	ADCY3 ADCY9 ADO ANKLE1 BAIAP2L2 C11orf80 C5orf35 CRISPLD1 CTD-2310F14.1 CYBRD1 CYP51A1 DIRC3 EXOC3 FES GPBP1L1 LRRC37A4P MAN2C1 MAP3K1 NEK10 NRBF2 PINLYP PRSS45 PVT1 RP11-196G18.24 RP11-250B2.5 RP11-500G22.2 RP11-73O6.3 RP11-848P1.7 SEMA4A SETD9 SGCE SLC4A7 SMC2 SNRPE SSBP4 TNNT3 UQCRQ ZBTB38
Standing height	2.67	27	22	48.9	0.08	6.8e-01	ADCY3 ADCY9 BAIAP2L2 C11orf80 C5orf35 CRISPLD1 CTD-2310F14.1 CYBRD1 CYP51A1 DIRC3 EXOC3 GPBP1L1 LRRC37A4P MAN2C1 MAP3K1 PRSS45 PVT1 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SEMA4A SETD9 SLC4A7 SNRPE SSBP4 UQCRQ ZBTB38
Allergy or Eczema	2.51	8	3	6.7	0.12	7.8e-01	CHEK2 DKFZp761E198 NAGLU SSBP4 TLR1 ULK3 UQCRQ ZBTB38
Medication: Metformin	2.50	1	1	2.2	0.00	1.0e+00	TCF7L2
Diabetes diagnosed by doctor	2.50	3	1	2.2	0.00	1.0e+00	IER2 RCCD1 TCF7L2
Comparative height size at age 10	2.47	17	13	28.9	0.07	7.6e-01	ADCY3 ADCY9 BAIAP2L2 C5orf35 CRISPLD1 DIRC3 GPBP1L1 LRRC37A4P MAP3K1 PRSS45 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SETD9 SNRPE UQCRQ ZBTB38
High blood pressure	2.44	10	6	13.3	-0.29	3.1e-01	ADO C6orf97 FES HSPA4 MLLT10 NEK10 NRBF2 SLC4A7 TNNT3 ULK3
Ovarian Cancer	2.41	5	3	6.7	0.19	6.6e-01	ANKLE1 CHEK2 LRRC37A4P MLLT10 RCCD1
Hayfever, allergic rhinitis or eczema	2.41	6	4	8.9	0.39	4.5e-01	DKFZp761E198 NAGLU TLR1 ULK3 UQCRQ ZBTB38
Vascular/heart problems diagnosed by doctor	2.39	9	6	13.3	0.21	5.2e-01	ADO C6orf97 FES HSPA4 MLLT10 NEK10 SLC4A7 TNNT3 ULK3
Sitting height	2.35	21	15	33.3	0.02	9.2e-01	ADCY3 BAIAP2L2 C5orf35 CRISPLD1 CTD-2310F14.1 CYBRD1 DIRC3 GPBP1L1 LRRC37A4P MAN2C1 MAP3K1 NEK10 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SETD9 SLC4A7 SSBP4 STXBP4 UQCRQ ZBTB38
Hypertension (Self-reported)	2.35	11	6	13.3	-0.29	3.0e-01	ADCY9 ADO C6orf97 FES HSPA4 MLLT10 NEK10 NRBF2 SLC4A7 TNNT3 ULK3
Type 2 Diabetes (T2D) (2018)	2.34	2	2	4.4	0.00	1.0e+00	MAN2C1 TCF7L2
Blood Platelet Count	2.33	28	21	46.7	-0.10	6.0e-01	AC068831.6 ADO ALS2CR12 C22orf23 CBX8 CDKN2B CHEK2 CYP51A1 DKFZp761E198 EXOC3 GATAD2A GBAP1 GDAP2 GPBP1L1 HSF2 LRRC37A4P MAN2C1 MFSD2A NEK10 NRBF2 RAD51L1 RALB RCCD1 RIN3 RP11-848P1.7 SLC4A7 SMC2 UQCRQ
Medication: Blood pressure	2.32	5	4	8.9	-0.30	4.7e-01	FES NEK10 SLC4A7 TNNT3 ULK3
Impedance of whole body	2.30	23	17	37.8	-0.15	4.6e-01	ADCY3 ADSL ANKLE1 C5orf35 CBX8 CTD-2310F14.1 CYBRD1 DIRC3 DKFZp761E198 GATAD2A LRRC37A4P MAP3K1 MKL1 NAGLU NRBF2 PEX14 POLR2J RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 SLC25A17 SLC4A7
Trunk fat-free mass	2.29	18	10	22.2	0.12	5.9e-01	ADCY9 ADSL ANKLE1 CBX8 CYBRD1 CYP51A1 DIRC3 GATAD2A MAN2C1 MKL1 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SLC4A7 SNRPE UQCRQ ZBTB38
Impedance of arm (left)	2.29	25	14	31.1	-0.18	3.4e-01	ADSL ANKLE1 BAIAP2L2 C5orf35 CBX8 CTD-2310F14.1 CYBRD1 DIRC3 DKFZp761E198 LRRC37A4P MAP3K1 MKL1 MLLT10 NRBF2 PEX14 POLR2J RASA4 RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 SLC25A17 SLC4A7 TCF7L2 TNNT3
Trunk predicted mass	2.29	18	10	22.2	0.18	4.6e-01	ADCY9 ADSL ANKLE1 CBX8 CYBRD1 CYP51A1 DIRC3 GATAD2A MAN2C1 MKL1 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SLC4A7 SNRPE UQCRQ ZBTB38
Diabetes (self-reported)	2.26	2	1	2.2	0.00	1.0e+00	IER2 TCF7L2
Allergy	2.25	5	4	8.9	-0.72	1.7e-01	DKFZp761E198 PEX14 TLR1 UQCRQ ZBTB38
Impedance of arm (right)	2.21	23	14	31.1	-0.19	3.4e-01	ADSL BAIAP2L2 CBX8 CTD-2310F14.1 CYBRD1 DIRC3 DKFZp761E198 LRRC37A4P MAP3K1 MKL1 MLLT10 NEK10 NRBF2 PEX14 POLR2J RASA4 RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 SLC25A17 SLC4A7 TCF7L2
Whole body water mass	2.20	17	10	22.2	0.33	1.7e-01	ADCY9 ADSL ANKLE1 CBX8 CYBRD1 DIRC3 GATAD2A GBAP1 MAN2C1 MKL1 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SNRPE UQCRQ ZBTB38
Whole body fat-free mass	2.19	18	10	22.2	0.24	3.1e-01	ADCY9 ADSL ANKLE1 CBX8 CYBRD1 DIRC3 GATAD2A GBAP1 MAN2C1 MKL1 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SLC4A7 SNRPE UQCRQ ZBTB38
Medication: Amlodipine	2.17	4	3	6.7	0.55	4.5e-01	FES NEK10 SLC4A7 TNNT3
Arm fat-free mass (left)	2.17	14	10	22.2	0.30	2.6e-01	ADCY9 ADSL ANKLE1 CBX8 CYBRD1 DIRC3 MAN2C1 MKL1 MLLT10 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 ZBTB38
Forced vital capacity (FVC)	2.16	12	8	17.8	0.41	1.7e-01	ADCY3 CCND1 CTD-2310F14.1 LRRC37A4P MAN2C1 MAP3K1 MLLT10 RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 ZBTB38
Arm fat-free mass (right)	2.14	14	9	20.0	0.26	3.2e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 MAN2C1 MKL1 MLLT10 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SNRPE ZBTB38
Arm predicted mass (right)	2.14	14	11	24.4	0.26	3.3e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 MAN2C1 MKL1 MLLT10 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 SNRPE ZBTB38
Arm predicted mass (left)	2.14	13	8	17.8	0.29	3.0e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 MAN2C1 MKL1 MLLT10 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 ZBTB38
Impedance of leg (left)	2.11	20	14	31.1	-0.15	4.8e-01	ADCY3 ADSL C5orf35 CBX8 CTD-2310F14.1 CYBRD1 DIRC3 DKFZp761E198 FES GATAD2A GBAP1 LRRC37A4P MAP3K1 MKL1 NAGLU PPP2R1B RIN3 RP11-73O6.3 SETD9 SLC25A17
Impedance of leg (right)	2.10	21	14	31.1	-0.19	3.4e-01	ADCY3 ADSL C5orf35 CBX8 CTD-2310F14.1 CYBRD1 DIRC3 DKFZp761E198 FES GATAD2A GBAP1 LRRC37A4P MAP3K1 MKL1 NAGLU POLR2J PPP2R1B RIN3 RP11-73O6.3 SETD9 SLC25A17
Basal metabolic rate	2.10	16	7	15.6	0.25	3.1e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 GATAD2A GBAP1 MAN2C1 MKL1 MLLT10 RIN3 RP11-73O6.3 RP11-848P1.7 SLC25A17 UQCRQ ZBTB38
High blood pressure (mother)	2.07	3	1	2.2	0.00	1.0e+00	FES SLC4A7 TNNT3
Forced expiratory volume in 1-second (FEV1)	2.02	14	6	13.3	0.33	2.3e-01	ADCY3 ADO CBX8 CCND1 CYBRD1 HSPA4 LRRC37A4P MAN2C1 MAP3K1 RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 ZBTB38
Leg fat-free mass (right)	2.01	16	11	24.4	0.29	2.4e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 FES GATAD2A GBAP1 MKL1 RIN3 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SLC25A17 UQCRQ ZBTB38
Leg predicted mass (right)	2.01	17	11	24.4	0.30	2.1e-01	ADCY9 ADSL CBX8 CYBRD1 DIRC3 FES GATAD2A GBAP1 MAN2C1 MKL1 RIN3 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SLC25A17 UQCRQ ZBTB38
Medication: Blood pressure	2.01	5	5	11.1	0.08	8.8e-01	FES LRRC37A4P SLC4A7 TNNT3 ULK3
Leg fat-free mass (left)	2.00	18	10	22.2	0.24	3.1e-01	ADCY9 ADSL BAIAP2L2 CBX8 CYBRD1 DIRC3 FES GATAD2A GBAP1 MKL1 MLLT10 RIN3 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SLC25A17 UQCRQ ZBTB38
Leg predicted mass (left)	1.99	17	10	22.2	0.25	2.9e-01	ADCY9 ADSL BAIAP2L2 CYBRD1 DIRC3 FES GATAD2A GBAP1 MKL1 MLLT10 RIN3 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 SLC25A17 UQCRQ ZBTB38
Forced vital capacity (FVC), Best measure	1.98	9	8	17.8	0.05	8.9e-01	ADCY3 LRRC37A4P MAN2C1 MLLT10 RIN3 RP11-196G18.24 RP11-73O6.3 SETD9 ZBTB38
Forced expiratory volume in 1-second (FEV1), predicted	1.97	5	4	8.9	-0.48	4.1e-01	ADCY3 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 ZBTB38
Hair/balding pattern: Pattern 4	1.96	3	2	4.4	0.00	1.0e+00	HSPA4 LRRC37A4P ZBTB38
Cardiovascular Disease	1.91	8	7	15.6	-0.02	9.6e-01	ADCY9 ADO FES HSPA4 NEK10 SLC4A7 TNNT3 ULK3
Medication: Bendroflumethiazide	1.91	4	2	4.4	0.31	6.1e-01	FES SLC4A7 TNNT3 ULK3
Diastolic blood pressure, automated reading	1.91	8	5	11.1	0.34	4.1e-01	ADO ADSL FES MIER3 MLLT10 NRBF2 TNNT3 ULK3
Systolic blood pressure, automated reading	1.89	8	6	13.3	-0.15	7.1e-01	ADO FES GPBP1L1 LRRC37A4P SLC4A7 TNNT3 TOX3 ULK3
Forced expiratory volume in 1-second (FEV1), Best measure	1.88	14	5	11.1	0.25	3.9e-01	ADCY3 ADO CBX8 CCND1 HSPA4 LRRC37A4P MAN2C1 MAP3K1 RIN3 RP11-196G18.24 RP11-73O6.3 RP11-982M15.2 SETD9 ZBTB38
Diabetes (father)	1.85	1	1	2.2	0.00	1.0e+00	TCF7L2
Hypothyroidism (self reported)	1.82	3	1	2.2	0.00	1.0e+00	DCLRE1B RIN3 TLR1
Medication: Gliclazide	1.82	1	1	2.2	0.00	1.0e+00	TCF7L2
Weight	1.81	14	11	24.4	0.08	7.8e-01	ADCY3 ADCY9 ADSL BAIAP2L2 CBX8 CYBRD1 DIRC3 DKFZp761E198 MLLT10 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 TCF7L2 ZBTB38
Rheumatoid Arthritis	1.79	1	1	2.2	0.00	1.0e+00	DCLRE1B
Illnesses of father: High blood pressure	1.79	1	1	2.2	0.00	1.0e+00	FES
Basal cell carcinoma (self-reported)	1.79	2	2	4.4	0.00	1.0e+00	ALS2CR12 CDKN2B
Crohns Disease (2017)	1.78	8	6	13.3	-0.05	9.0e-01	ADCY3 ADCY9 DCLRE1B GBAP1 NAGLU UQCRQ USP3 ZBTB38
Diabetes (mother)	1.78	1	1	2.2	0.00	1.0e+00	TCF7L2
Waist Hip Ratio (WHR)	1.77	13	9	20.0	-0.07	8.3e-01	CTD-2310F14.1 CYBRD1 HSPA4 KIF9-AS1 LRRC37A4P MAN2C1 PPP2R1B PVT1 RP11-250B2.5 RP11-554A11.9 RP11-73O6.3 TCF7L2 ZBTB38
Osteoporosis (self-reported)	1.76	1	0	0.0	0.00	1.0e+00	RCCD1
Hypothyroidism/myxoedema (self-reported)	1.75	1	1	2.2	0.00	1.0e+00	DCLRE1B
Type 2 Diabetes (T2D) (2012)	1.73	1	1	2.2	0.00	1.0e+00	TCF7L2
Medication for cholesterol, blood pressure or diabetes	1.72	3	2	4.4	-0.95	4.9e-02	FES NEK10 SLC4A7
Crohns Disease (2012)	1.71	4	1	2.2	-0.61	3.9e-01	GBAP1 NAGLU UQCRQ USP3
BMI	1.71	16	9	20.0	0.31	1.9e-01	ADCY3 ADCY9 ADSL C22orf23 CBX8 CYBRD1 DKFZp761E198 GPBP1L1 MKL1 MLLT10 NRBF2 RP11-73O6.3 RPLP2 SLC25A17 TCF7L2 TLR1
Prostate Cancer	1.70	1	1	2.2	0.00	1.0e+00	RP11-554A11.9
Hand grip strength (right)	1.70	9	6	13.3	0.37	3.3e-01	ADCY3 CBX8 CYBRD1 LRRC37A4P MAN2C1 MLLT10 PEX14 RP11-73O6.3 ZBTB38
Supplements: Zinc	1.69	1	1	2.2	0.00	1.0e+00	NRBF2
Asthma	1.69	3	3	6.7	0.00	1.0e+00	PEX14 TLR1 UQCRQ
Birth weight of first child	1.68	2	2	4.4	0.00	1.0e+00	FES ZBTB38
Asthma (self-reported)	1.68	3	3	6.7	0.00	1.0e+00	PEX14 TLR1 UQCRQ
Hand grip strength (left)	1.67	7	5	11.1	0.30	5.2e-01	ADCY3 ADSL CBX8 IER2 LRRC37A4P RP11-73O6.3 ZBTB38
High blood pressure (siblings)	1.67	4	2	4.4	0.57	4.3e-01	ADO FES SLC4A7 TNNT3
Mouth/teeth dental problems: Mouth ulcers	1.65	2	2	4.4	0.00	1.0e+00	CEBPB LRRC37A4P
Lung FEV1/FVC ratio	1.63	15	10	22.2	0.13	6.2e-01	ADCY3 ADO ATE1 C22orf23 GPBP1L1 HSPA4 LRRC37A4P MCHR1 MKL1 MLLT10 NRBF2 RP11-53O19.3 SLC25A17 UQCRQ ZBTB38
Blood Red Count	1.61	21	15	33.3	0.10	6.6e-01	ADO ADSL ATXN7 BAIAP2L2 C11orf80 C6orf108 CYP51A1 EXOC3 GBAP1 GPBP1L1 IER2 LRRC37A4P MAN2C1 MFSD2A NRBF2 RANBP9 RP11-73O6.3 SSBP4 TLR1 ULK3 ZBTB38
Trunk fat mass	1.61	9	7	15.6	-0.08	8.3e-01	ADCY3 ADCY9 BAIAP2L2 C22orf23 MLLT10 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 ZBTB38
Hayfever/allergic rhinitis (self-reported)	1.61	1	1	2.2	0.00	1.0e+00	TLR1
Trunk fat percentage	1.60	8	7	15.6	-0.13	7.6e-01	ADCY3 BAIAP2L2 C22orf23 LRRC37A4P MLLT10 RIN3 RP11-196G18.24 ZBTB38
Body mass index (BMI)	1.60	12	6	13.3	0.32	2.6e-01	ADCY3 ADSL C22orf23 CBX8 DKFZp761E198 GPBP1L1 MKL1 MLLT10 NRBF2 RP11-73O6.3 SLC25A17 TCF7L2
Illnesses of father: None of the above (group 1)	1.60	1	1	2.2	0.00	1.0e+00	FES
Eye problems/disorders: Diabetes related eye disease	1.59	1	0	0.0	0.00	1.0e+00	TCF7L2
Arm fat percentage (right)	1.58	7	5	11.1	0.40	3.7e-01	ADCY3 ADSL BAIAP2L2 C22orf23 MLLT10 RP11-196G18.24 TCF7L2
Irritable Bowel Disease (IBD)	1.57	5	4	8.9	-0.09	8.8e-01	ADCY3 GBAP1 NAGLU UQCRQ USP3
Whole body fat mass	1.57	11	7	15.6	0.15	6.6e-01	ADCY3 ADCY9 ADSL BAIAP2L2 C22orf23 DKFZp761E198 MLLT10 RP11-196G18.24 RP11-73O6.3 TCF7L2 ZBTB38
Leg fat mass (right)	1.57	10	7	15.6	0.32	3.4e-01	ADCY3 ADSL BAIAP2L2 C22orf23 DKFZp761E198 KIF9-AS1 MLLT10 RP11-73O6.3 TCF7L2 ZBTB38
Arm fat percentage (left)	1.57	7	5	11.1	0.39	3.8e-01	ADCY3 ADSL BAIAP2L2 C22orf23 MLLT10 RP11-196G18.24 TCF7L2
Angina	1.56	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Body fat percentage	1.56	8	6	13.3	0.09	8.4e-01	ADCY3 BAIAP2L2 C22orf23 MLLT10 RIN3 RP11-196G18.24 TCF7L2 ZBTB38
Leg fat percentage (right)	1.56	8	6	13.3	0.08	8.5e-01	ADCY3 BAIAP2L2 C22orf23 GPBP1L1 MAN2C1 MLLT10 RIN3 TCF7L2
Arm fat mass (left)	1.56	12	6	13.3	0.34	2.5e-01	ADCY3 ADSL BAIAP2L2 C22orf23 CYBRD1 DKFZp761E198 MKL1 MLLT10 RP11-196G18.24 RP11-73O6.3 TCF7L2 ZBTB38
Leg fat mass (left)	1.56	10	7	15.6	0.32	3.3e-01	ADCY3 ADSL BAIAP2L2 C22orf23 DKFZp761E198 KIF9-AS1 MLLT10 RP11-73O6.3 TCF7L2 ZBTB38
Bipolar Disorder or Schizophrenia	1.55	6	3	6.7	-0.66	1.1e-01	C6orf108 FES GATAD2A MCHR1 MRPS30 RP11-53O19.3
Coronary Artery Disease (CAD)	1.55	1	1	2.2	0.00	1.0e+00	CDKN2B
Birth weight	1.55	3	1	2.2	0.00	1.0e+00	ADCY9 FES RP11-73O6.3
Medication: Levothyroxine sodium	1.54	1	1	2.2	0.00	1.0e+00	DCLRE1B
Arm fat mass (right)	1.54	11	7	15.6	0.30	3.5e-01	ADCY3 ADSL BAIAP2L2 C22orf23 DKFZp761E198 MKL1 MLLT10 RP11-196G18.24 RP11-73O6.3 TCF7L2 ZBTB38
Lung FVC	1.53	14	7	15.6	0.45	8.8e-02	ANTXR1 C11orf80 CBX8 DIRC3 GBAP1 HSPA4 LRRC37A4P MAN2C1 MAP3K1 MLLT10 RIN3 RP11-848P1.7 RP11-982M15.2 ZBTB38
Hip circumference	1.53	9	8	17.8	0.09	8.2e-01	ADCY3 BAIAP2L2 CYBRD1 MLLT10 RP11-196G18.24 RP11-73O6.3 RP11-848P1.7 TCF7L2 ZBTB38
Angina (self-reported)	1.53	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Leg fat percentage (left)	1.53	6	6	13.3	0.09	8.6e-01	ADCY3 C22orf23 GPBP1L1 MLLT10 RIN3 TCF7L2
Ever had prostate specific antigen (PSA) test	1.53	2	0	0.0	0.00	1.0e+00	PEX14 ZBTB38
Relative age of first facial hair	1.49	3	1	2.2	0.00	1.0e+00	HSPA4 LRRC37A4P ZBTB38
Handedness (chirality/laterality): Left-handed	1.49	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Schizophrenia (2018)	1.48	4	1	2.2	-0.93	2.3e-02	FES GATAD2A MRPS30 RP11-53O19.3
Schizophrenia (2014)	1.47	6	2	4.4	-0.55	2.0e-01	FES GATAD2A MCHR1 MRPS30 RP11-53O19.3 SLC25A17
Waist circumference	1.47	10	4	8.9	-0.05	8.9e-01	ADCY3 ADCY9 ADSL C22orf23 C3orf26 KIF9-AS1 MKL1 MLLT10 NRBF2 ZBTB38
Respiratory disease	1.46	4	2	4.4	0.99	1.1e-02	PEX14 RIN3 TLR1 UQCRQ
Sensitivity / hurt feelings	1.46	2	2	4.4	0.00	1.0e+00	GATAD2A LRRC37A4P
Medication for cholesterol	1.46	1	1	2.2	0.00	1.0e+00	TNNT3
Illnesses of father: Heart disease	1.42	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Bilateral oophorectomy (both ovaries removed)	1.40	1	0	0.0	0.00	1.0e+00	MLLT10
Illnesses of mother	1.40	1	1	2.2	0.00	1.0e+00	FES
Peak expiratory flow (PEF)	1.40	2	1	2.2	0.00	1.0e+00	LRRC37A4P SMC2
Number of operations (self-reported)	1.40	1	0	0.0	0.00	1.0e+00	MLLT10
Number of live births	1.38	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Medication: Paracetamol	1.38	2	1	2.2	0.00	1.0e+00	LRRC37A4P MLLT10
Reproduciblity of spirometry measurement using ERS/ATS criteria	1.37	1	0	0.0	0.00	1.0e+00	GBAP1
Ever had hysterectomy (womb removed)	1.36	1	0	0.0	0.00	1.0e+00	MLLT10
Body Mass Index (BMI) (2010)	1.35	1	1	2.2	0.00	1.0e+00	ADCY3
Illnesses of siblings: Diabetes	1.35	1	1	2.2	0.00	1.0e+00	TCF7L2
Ulcerative Colitis (UC)	1.34	2	0	0.0	0.00	1.0e+00	GBAP1 NAGLU
Gout (self-reported)	1.34	1	1	2.2	0.00	1.0e+00	PPM1K
Medication: Allopurinol	1.34	1	1	2.2	0.00	1.0e+00	PPM1K
Medication: Paracetamol	1.34	2	1	2.2	0.00	1.0e+00	LRRC37A4P MLLT10
Medication: Lisinopril	1.34	1	0	0.0	0.00	1.0e+00	ADO
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.32	3	2	4.4	0.00	1.0e+00	CBX8 LRRC37A4P RIN3
Father's age at death	1.31	1	0	0.0	0.00	1.0e+00	FES
Pulse rate, automated reading	1.30	6	2	4.4	-0.61	1.1e-01	ANKLE1 HSPA4 MRPS30 NEK10 RP11-53O19.3 ZBTB38
Fractured/broken bones in last 5 years	1.30	1	1	2.2	0.00	1.0e+00	C6orf97
Nervous feelings	1.27	2	1	2.2	0.00	1.0e+00	CBX8 LRRC37A4P
Headache pain in last month	1.26	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Bipolar Disorder (2018)	1.25	1	1	2.2	0.00	1.0e+00	MCHR1
Taking other prescription medications	1.24	2	0	0.0	0.00	1.0e+00	DCLRE1B GATAD2A
Illnesses of siblings	1.24	1	0	0.0	0.00	1.0e+00	FES
Medication: Cholesterol lowering	1.24	2	0	0.0	0.00	1.0e+00	FES GATAD2A
Average weekly red wine intake	1.24	2	0	0.0	0.00	1.0e+00	C11orf80 ULK3
Supplements: Fish oil (including cod liver oil)	1.24	1	0	0.0	0.00	1.0e+00	C11orf80
Ever unenthusiastic/disinterested for a whole week	1.23	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Heart attack/myocardial infarction (self-reported)	1.21	1	0	0.0	0.00	1.0e+00	FES
Past tobacco smoking	1.20	3	0	0.0	0.00	1.0e+00	C22orf23 CBX8 MLLT10
Mineral and other dietary supplements	1.19	1	0	0.0	0.00	1.0e+00	NRBF2
Lupus	1.18	1	0	0.0	0.00	1.0e+00	DCLRE1B
Triglycerides	1.18	3	1	2.2	0.00	1.0e+00	BAIAP2L2 GATAD2A NRBF2
Blood Eosinophil Count	1.18	11	6	13.3	0.09	8.0e-01	ADCY3 ADSL CYP51A1 DKFZp761E198 GATAD2A LRRC37A4P NRBF2 PPP2R1B RIN3 RP11-73O6.3 UQCRQ
Blood White Count	1.18	19	14	31.1	0.15	5.3e-01	ALS2CR12 CDKN2B DCLRE1B DIRC3 FES HSF2 KIF9-AS1 LRRC37A4P MAN2C1 MFSD2A NEK10 NRBF2 PEX14 PRSS45 RIN3 RP11-73O6.3 SLC4A7 SSBP4 UQCRQ
Chronotype (morning person)	1.18	4	1	2.2	-0.33	5.9e-01	ADCY3 ADSL RASA4 RP11-500G22.2
Hearing difficulty/problems with background noise	1.18	2	1	2.2	0.00	1.0e+00	LRRC37A4P ULK3
Heart attack	1.18	1	0	0.0	0.00	1.0e+00	FES
Medication: Aspirin	1.18	1	0	0.0	0.00	1.0e+00	FES
Hearing difficulty/problems: Yes	1.17	1	0	0.0	0.00	1.0e+00	GPBP1L1
Medication: Atenolol	1.17	1	1	2.2	0.00	1.0e+00	FES
Hair/balding pattern: Pattern 2	1.16	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Medication: Simvastatin	1.16	1	0	0.0	0.00	1.0e+00	FES
Age at first live birth	1.16	1	0	0.0	0.00	1.0e+00	GATAD2A
Age when periods started (menarche)	1.15	3	1	2.2	0.00	1.0e+00	ADCY3 C22orf23 LRRC37A4P
Medication: Ventolin 100micrograms inhaler	1.15	2	0	0.0	0.00	1.0e+00	TLR1 UQCRQ
Pain experienced in last month	1.15	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Frequency of tiredness / lethargy in last 2 weeks	1.14	1	0	0.0	0.00	1.0e+00	SSBP4
Mean time to correctly identify matches	1.14	2	0	0.0	0.00	1.0e+00	C22orf23 RP11-73O6.3
Number of self-reported non-cancer illnesses	1.14	1	0	0.0	0.00	1.0e+00	MLLT10
Worry (Nagel 2018)	1.13	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Pulse rate	1.13	1	1	2.2	0.00	1.0e+00	ZBTB38
Smoking status: Previous	1.13	1	0	0.0	0.00	1.0e+00	CBX8
Myopia	1.12	1	0	0.0	0.00	1.0e+00	GATAD2A
Multivitamins +/- minerals	1.11	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Aspirin	1.11	1	0	0.0	0.00	1.0e+00	FES
Ever smoked	1.11	1	0	0.0	0.00	1.0e+00	GPBP1L1
Number of treatments/medications taken	1.10	2	1	2.2	0.00	1.0e+00	DCLRE1B MLLT10
Hair/balding pattern: Pattern 3	1.10	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Relative age voice broke	1.09	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Medication for pain relief, constipation, heartburn	1.09	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Supplements: Glucosamine	1.08	2	0	0.0	0.00	1.0e+00	NRBF2 ULK3
Mood swings	1.08	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Primary Biliary Cirrhosis	1.06	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Mouth/teeth dental problems: Dentures	1.06	1	1	2.2	0.00	1.0e+00	GBAP1
Worry too long after embarrassment	1.06	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Medication: Atorvastatin	1.06	1	0	0.0	0.00	1.0e+00	TCF7L2
Long-standing illness, disability or infirmity	1.05	1	0	0.0	0.00	1.0e+00	DCLRE1B
Guilty feelings	1.05	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Irritability	1.05	2	1	2.2	0.00	1.0e+00	LRRC37A4P RP11-73O6.3
Intelligence (Savage-Jansen 2018)	1.04	3	2	4.4	0.00	1.0e+00	C22orf23 LRRC37A4P NRBF2
Neuroticism (2016)	1.03	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Medication: Ibuprofen	1.03	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Neuroticism (Nagel 2018)	1.02	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Smoking Status	1.02	3	1	2.2	0.00	1.0e+00	CBX8 GPBP1L1 MLLT10
Fed-up feelings	1.02	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Qualifications: College or University degree	1.02	5	1	2.2	0.43	4.7e-01	GPBP1L1 IER2 LRRC37A4P MLLT10 NRBF2
Alcohol drinker status: Previous	1.02	1	0	0.0	0.00	1.0e+00	IER2
Mouth/teeth dental problems	1.01	1	0	0.0	0.00	1.0e+00	GBAP1
Medication: Ibuprofen (e.g. Nurofen)	1.00	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Average weekly champagne plus white wine intake	1.00	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Verbal and Numeric Reasoning (VNR)	0.99	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Neuroticism	0.98	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Frequency of tenseness / restlessness in last 2 weeks	0.98	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Overall health rating	0.98	1	0	0.0	0.00	1.0e+00	MLLT10
Cholesterol lowering medication	0.98	1	0	0.0	0.00	1.0e+00	TCF7L2
Neuroticism score	0.95	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Worrier / anxious feelings	0.94	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Depression (Nagel 2018)	0.93	1	0	0.0	0.00	1.0e+00	LRRC37A4P
Depressed Affect (Nagel 2018)	0.92	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Maternal smoking around birth	0.90	1	0	0.0	0.00	1.0e+00	MLLT10
Alcohol intake frequency.	0.88	2	1	2.2	0.00	1.0e+00	LRRC37A4P ULK3
High cholesterol (Self-reported)	0.86	1	1	2.2	0.00	1.0e+00	GATAD2A
Qualifications: None of the above	0.81	1	1	2.2	0.00	1.0e+00	NRBF2
Miserableness	0.76	1	1	2.2	0.00	1.0e+00	LRRC37A4P
Hair Pigment	0.49	16	9	20.0	-0.06	8.2e-01	ADCY3 ARHGEF5 CCND1 CTD-2310F14.1 CYP51A1 FES GBAP1 LRRC37A4P MIER3 PEX14 PPP2R1B RP11-554A11.9 RP11-73O6.3 SSBP4 TOX3 ZBTB38
Tanning	0.30	7	4	8.9	0.20	6.6e-01	ADCY3 ADO BAIAP2L2 CYBRD1 GBAP1 LINC00886 RP11-554A11.9

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Putamen basal ganglia	11	1.85	3.3
GTEx	Brain Frontal Cortex BA9	15	1.69	3.2
GTEx	Brain Nucleus accumbens basal ganglia	14	1.69	3.1
GTEx	Spleen	23	1.69	3.1
GTEx	Brain Hypothalamus	9	1.56	3.0
GTEx	Brain Caudate basal ganglia	13	1.47	2.9
GTEx	Brain Cortex	16	1.59	2.9
GTEx	Breast Mammary Tissue	32	1.69	2.9
GTEx	Breast Mammary Tissue (Male)	19	1.67	2.9
GTEx	Stomach	23	1.65	2.9
GTEx	Adipose Visceral Omentum	22	1.14	2.8
GTEx	Artery Coronary	19	1.67	2.8
GTEx	Brain Hippocampus	7	1.40	2.8
GTEx	Breast Mammary Tissue (Female)	20	1.28	2.8
GTEx	Cells EBV-transformed lymphocytes	22	1.62	2.8
GTEx	Colon Sigmoid	22	1.59	2.8
GTEx	Heart Atrial Appendage	19	1.25	2.8
GTEx	Pancreas	22	1.41	2.8
GTEx	Whole Blood	26	1.36	2.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	42	1.00	2.8
GTEx	Adrenal Gland	14	1.01	2.7
GTEx	Artery Aorta	32	1.13	2.7
GTEx	Brain Cerebellar Hemisphere	16	1.12	2.7
GTEx	Brain Cerebellum	24	1.26	2.7
GTEx	Colon Transverse	28	1.42	2.7
GTEx	Esophagus Mucosa	37	1.16	2.7
GTEx	Esophagus Muscularis	33	1.07	2.7
GTEx	Liver	7	1.02	2.7
GTEx	Lung	33	1.20	2.7
GTEx	Skin Not Sun Exposed Suprapubic	26	1.11	2.7
GTEx	Small Intestine Terminal Ileum	8	1.82	2.7
GTEx	Uterus	7	1.28	2.7
GTEx	Vagina	9	1.49	2.7
GTEx	Adipose Subcutaneous	31	0.93	2.6
GTEx	Artery Tibial	40	1.12	2.6
GTEx	Esophagus Gastroesophageal Junction	14	1.01	2.6
GTEx	Heart Left Ventricle	14	0.95	2.6
GTEx	Muscle Skeletal	29	1.05	2.6
GTEx	Nerve Tibial	39	0.95	2.6
GTEx	Ovary	11	1.26	2.6
GTEx	Pituitary	12	1.12	2.6
GTEx	Prostate	11	1.37	2.6
GTEx	Skin Sun Exposed Lower leg	37	1.06	2.6
GTEx	Testis	36	1.20	2.6
GTEx	Thyroid	46	1.20	2.6
The Cancer Genome Atlas	Glioblastoma Multiforme	14	1.42	2.6
GTEx	Cells Transformed fibroblasts	37	0.92	2.5
The Cancer Genome Atlas	Colon Adenocarcinoma	23	1.17	2.5
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	24	1.23	2.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	13	0.82	2.5
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	4	0.82	2.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	27	1.05	2.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	32	0.82	2.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	37	0.90	2.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	10	0.95	2.4
The Cancer Genome Atlas	Lung Adenocarcinoma	27	0.96	2.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	15	0.99	2.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	16	1.00	2.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.63	2.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	31	0.70	2.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	10	0.98	2.4
NTR	Blood	18	0.80	2.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	8	0.76	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	8	1.21	2.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	14	0.59	2.3
The Cancer Genome Atlas	Thyroid Carcinoma	33	0.67	2.3
METSIM	Adipose	31	0.71	2.2
ROSMAP	Brain Pre-frontal Cortex	20	0.47	2.2
YFS	Blood	29	0.67	2.2
CommonMind	Brain Pre-frontal Cortex	41	0.80	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.58	2.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	2	0.39	2.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.25	2.2
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.30	2.1